Cargando…
RF19 | PSUN349 Histone Eraser and Reader Targeting Epigenetic Inhibitors Are Effective in Pancreatic Neuroendocrine Tumours
BACKGROUND: The 5-year survival for metastatic pancreatic neuroendocrine tumours (PNETs) is <50%, and current therapies are not effective. Thus, there is an unmet clinical need for new therapies for patients with PNETs. PNETs frequently have mutations in chromatin remodelling genes, including in...
Autores principales: | Carmichael, James, Escoubet, Laure, Lines, Kate, Mavrommatis, Konstantinos, Mortensen, Deborah, Thakker, Rajesh V, Thakurta, Anjan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629168/ http://dx.doi.org/10.1210/jendso/bvac150.1859 |
Ejemplares similares
-
RF05 | PSUN365 Insulinoma: A Case Report of a Rare Functioning Neuroendocrine Tumor
por: Pescador, Antonio, et al.
Publicado: (2022) -
RF07 | PSUN359 Alpelisib-induced Diabetic Ketoacidosis
por: Majumdar, Sachin, et al.
Publicado: (2022) -
RF19 | PSUN353 Liquid Biopsies - Detecting and Tracking Circulating Cell Free Tumor Derived DNA in Patients with Neuroendocrine Neoplasms
por: Gohil, Shailesh, et al.
Publicado: (2022) -
RF05 | PSUN341 Role of sirtuins in breast cancer cells response to Fulvestrant
por: Sengupta, Surojeet, et al.
Publicado: (2022) -
RF19 | PSUN351 Glycoprotein-NMB (GPNMB) is Pro-Tumorigenic in Lymphangioleiomyomatosis (LAM)
por: Gibbons, Erin, et al.
Publicado: (2022)